Core Viewpoint - Anhui Jiren Pharmaceutical Co., Ltd. is restarting its IPO process after previously withdrawing its application in February 2025, with the same underwriting team and legal and accounting firms involved in the new attempt [3][5]. Company Overview - Company Name: Anhui Jiren Pharmaceutical Co., Ltd. [5] - Established: April 19, 2001 (as a limited company), December 20, 2021 (as a joint-stock company) [7] - Industry: Pharmaceutical manufacturing [8] - Registered Capital: 361.81 million yuan [8] - Main Products: Modern Chinese medicine, including traditional Chinese medicine pieces and formula granules [5]. Financial Performance - Revenue from 2021 to the first half of 2024: 805 million yuan (2021), 1.025 billion yuan (2022), 1.134 billion yuan (2023), and 593 million yuan (first half of 2024) [5]. - Net profit for the same period: 95.17 million yuan (2021), 157 million yuan (2022), 131 million yuan (2023), and 80.16 million yuan (first half of 2024) [5]. - Total assets as of June 30, 2024: 1.627 billion yuan, with a total liability ratio of 51.67% [6]. - Basic earnings per share for the first half of 2024: 0.22 yuan [6]. Shareholding Structure - Controlling shareholder: Zhu Yuxin, holding 87.06% of the shares [8]. - Family members of Zhu Yuxin collectively control 99.12% of the shares [8][10].
济人药业拟闯关北交所：70岁董事长朱月信家族控股99%，儿子任副总
Sou Hu Cai Jing·2025-08-08 11:16